Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
THE REPRODUCTIVE SYSTEM
Guest Editors: Freeman L. M., Bombardieri E.
Freeman L. M., Krynyckyi B. R., Li, Y., Korupulu G., Saleemi K., Haseman M. K. *, Kahn D. **
Department of Nuclear Medicine Montefiore Medical Center and Albert Einstein College of Medicine Bronx, New York, USA
* Sutter Community Hospital ,Sacramento, CA, USA
** Jowa City Veterans Administration, Medical Center Jowa City, IA, USA
111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint’s role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.